Bavarian Nordic’s Post

Here learning alot about the bio waste industry.

Thoughts on this? >> FDA gives accelerated approval to PBC drug at the center of Gilead’s $4.3B CymaBay deal >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #biotech #productmarketing #pharmaceutical

Who's to blame for high drug prices? Depends on who you ask. The FTC has been exercising its agency muscles recently by going after both Big Pharma and Pharmacy Benefit Managers (PBMs) for their alleged roles in driving up drug prices. For Big Pharma, the FTC has been going after so-called "junk" patents that are allegedly driving up American drug prices and stifling competition. https://bit.ly/3Y5lm3x For PBMs, the FTC is suing the three big PBMs, alleging they're "steer[ing] patients to use more expensive drugs." https://bit.ly/3WoSXo5 There appears to be no love lost between Big Pharma and PBMs - both seem more than happy to throw each other under the bus: https://bit.ly/4bO3uh4 • The PhRMA (Pharmaceutical Research and Manufacturers of America ), the drugmaker's lobby, has praised the FTC's recent report on PBMs, calling them "[profiteering] corporate middlemen". • The PCMA (Pharmaceutical Care Management Association), the PBMs' lobby, is placing drug prices squarely on big pharma - a report last year (sponsored by PCMA), found that "PBMs account for just 6% of the net cost of a prescription while manufacturers account for 65%". —————————— Get the top biotech and pharma industry news, straight to your inbox and all in one email - that's TLDR Biotech. 🧬🔔 #biotech #pharma #pharmanews #biotechnews #tldrbiotech

Heading out to the annual conference for NCPDP (National Council for Prescription Drug Programs, Inc.) this morning! Looking forward to hearing more about what our #pharmacy partners are dealing with each day and how we can work together towards solutions. If you are in Scottsdale this week, send me a message so we can connect and collaborate! #inmarjourney #theyearoftheproduct #NCPDP24

Thoughts on this? >> FDA gives accelerated approval to PBC drug at the center of Gilead’s $4.3B CymaBay deal >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharma #pharmaceutical #productmarketing

Stay informed and monitor global drug prices daily🌍   Ex-PRICE helps you keep a close eye on daily drug prices, ensuring you’re always in the know about price changes. Our platform automatically collects data from publicly available sources across all monitored countries. With Ex-PRICE, you’ll receive daily updates on: ✅ Drug prices and price changes   ✅ New drug launches   ✅ Drug shortages and withdrawals  You will also gain access to a comprehensive 6-year history of drug prices, starting with the initial record of each specific drug in the system.   Don’t miss out on this valuable resource. ➡️Unlock Ex-PRICE’s full potential with a personalized demo at exprice.eu. Get in touch today!  #Pharmaceuticals #DrugPricing #ExPRICE #DataInsights 

The US FDA New Drug Approvals in February 2024 PharmaShots, your go-to media platform for life science news, brings a condensed report highlighting new drug approvals in February 2024 Stay Tuned for more updates! #takeda #usfda #approvals #regulatory #nda #february #february2024 #pharmashots #pharma #lifesciences

It's not new news that GLP-1s have taken the U.S. by storm. But, European patients are showing a surprising willingness to pay out-of-pocket for new weight-loss products like Novo Nordisk's Wegovy (semaglutide). So much so that parent company Novo Holdings just bought Catalent for $16.5B to give the Danish drugmaker three more production sites, to help bolster its supply chain. With talks of "flexible" pricing and the possibility of extending use to cardiovascular issues, what does the future of market access look like for this in-demand class of products? #Wegovy #GLP1s #weightloss #Ozempic #pharmaceuticals #marketaccess Read more here: https://lnkd.in/eCYWdFfz

In the wake of the significant attention GLP-1s like Wegovy are receiving across the U.S. and now Europe, it's an exciting time to reflect on the evolving landscape of weight loss solutions. The innovation behind these treatments, especially with their potential expansion into addressing cardiovascular issues, highlights a promising frontier in healthcare. However, it also opens up a dialogue about the holistic approach to wellness. How do we balance the breakthroughs in pharmaceuticals with the timeless principles of diet and exercise? Is there a way to integrate these advancements seamlessly into a broader wellness strategy that emphasizes sustainable health practices? The willingness of patients to invest in their health, even out-of-pocket, underscores a significant shift towards prioritizing wellness. Yet, this enthusiasm also brings to light questions of accessibility and equity. How can we ensure these life-changing treatments are within reach for everyone who needs them? I'm curious to hear your thoughts on how we can foster an inclusive environment in healthcare that values both innovation and traditional approaches to health and wellness. Let's discuss how we can support each other in navigating this exciting yet complex landscape. #Wegovy #GLP1s #weightloss #Ozempic #pharmaceuticals #marketaccess #healthyliving #sustainability #communitydiscussion" Read more here: https://lnkd.in/eCYWdFfz

We are thrilled to support Medtech Rising as a gold sponsor this year.     Be sure to stop by our stand and say hello to myself and the team. If you’d like to reserve time for a free consultation, book now: https://lnkd.in/eVxsVvF5    #MedtechRising #Medtech #MedtechConference #RegulatoryAffairs #MedicalDevices #InternationalConference